Big Tech Earnings, Fed's Interest Rate Decision To Keep Next Week Busy
Spero Therapeutics Inc SPRO
$1.17
▼ -2.50%
($-0.03)
🗓️ Earnings Next Week
Open
$1.20
Prev Close
$1.20
Day Range
$1.17 – $1.21
52W Range
$1.08 – $3.08
Market Cap
$67.74M
P/E (TTM)
4.45
Beta
1.47
EPS (TTM)
$0.17
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-11-02 |
| Shares Out. | 57,900,000 |
| Website | sperotherapeutics.com/ ↗ |
| Phone | 13026587581 |
| Employees | 25 |
| Revenue | $258,000 |
| Gross Profit | $258,000 |
| Net Income | -$7.2M |
| Total Assets | $59.0M |
| Total Liabilities | $6.1M |
| Equity | $52.9M |
About Spero Therapeutics Inc
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Spero Therapeutics Inc is a publicly traded company under the ticker symbol SPRO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)